CompletedNCT02501109
Aripiprazole Oral Film Compared With Tablet in Healthy Adults
About this title
Read the official source — NCT02501109Medication studyAges 45–65Schizophrenia
Understand this study
Who was this study for?
This study was for healthy volunteers. Listed age limits: 45 years to 65 years. Other eligibility criteria applied.
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateOctober 2015
- Recruitment status
- Completed
- Enrollment listed in the registry
- 36
- Sponsor
- CMG Pharmaceutical Co. Ltd
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Not clearly listed
- Age range
- From 45 Years to 65 Years
- Official registry ID
- NCT02501109
- Official title
Show the full official title
A Single-dose, Randomized, Three-period, Crossover Comparative Bioavailability Study of a Novel Formulation of Aripiprazole 10 mg Oral Soluble Film vs the Marketed Formulation Abilify® 10 mg Tablet in Healthy Volunteers
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Locations not listed
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is CMG Pharmaceutical Co. Ltd, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Aripiprazole.
Who was this study for?
This study was for healthy volunteers. Listed age limits: 45 years to 65 years. Other eligibility criteria applied.
